Sudeep Pharma share price made an impressive debut on the stock exchanges on Friday, listing at Rs 730 per share on the National Stock Exchange (NSE). This represents a solid premium of 23.10% over the initial public offering (IPO) price of Rs 593. Meanwhile, on the BSE, the stock opened at Rs 733.95, reflecting a 23.77% gain.
The strong listing delighted investors who received allotments. Each lot consisted of 25 shares. Consequently, investors made Rs 18,250 per lot from this successful debut.
Before listing, the IPO had attracted overwhelming demand. The subscription closed at 93.72 times, showing strong market confidence. Furthermore, qualified institutional buyers led the demand with 213.08 times the subscription. Non-institutional investors followed closely at 116.72 times, while retail investors subscribed 15.65 times.
The company raised Rs 895 crore through this offering. This included Rs 95 crore from fresh equity shares and Rs 800 crore through an offer for sale. Additionally, the company had secured Rs 268.5 crore from anchor investors before the public issue opened.
HTR#Sudeep Pharma Lists At A 23% Premium
– Company valued at around over 45x trailing FY25 P/E
– Rs 75 cr to be used for capex expansion for Iron phosphate: Management@ekta_batra #CNBCTV18Market pic.twitter.com/4WDHOo9hQr— CNBC-TV18 (@CNBCTV18News) November 28, 2025
Several prominent names participated in the anchor round. These included SBI Mutual Fund, ICICI Prudential MF, HDFC MF, and Nippon India MF. Moreover, insurance giants like SBI Life Insurance and Tata AIA Life Insurance also invested.
Sudeep Pharma operates as a technology-driven manufacturer in the pharmaceutical sector. The company produces excipients and specialty ingredients for the pharma, food, and nutrition industries. Currently, it runs six manufacturing facilities with a combined capacity of 50,000 metric tonnes.
The company’s product portfolio is impressive. It offers more than 200 products across various mineral-based ingredients. These include calcium, magnesium, iron, potassium, and zinc specialties. Additionally, the company supplies to over 100 countries globally.
The fresh issue has clear purposes. The company plans to use Rs 75.81 crore for procuring machinery at its Gujarat facility. The remaining funds will support general corporate purposes. This expansion should strengthen its production capabilities further.
Market experts view the listing positively. Master Capital Services highlighted the company’s strong competitive position and technology-driven processes. The brokerage believes Sudeep Pharma can benefit from long-term growth trends in specialty chemicals.
Financially, the company shows healthy performance. In FY25, it reported revenue of Rs 511.33 crore, marking a 10% increase. Net profit reached Rs 138.69 crore, maintaining robust margins of 27.6%.
Looking ahead, the industry outlook appears promising. India’s food and nutritional ingredients sector continues to expand rapidly. The market, valued at $22 billion in 2024, is projected to reach $32 billion by 2029.
In conclusion, Sudeep Pharma share price performance exceeded grey market expectations and demonstrated strong investor confidence. However, the company’s global presence and diversified product range position it well for future growth opportunities.
